Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial

Abstract Background Individuals with high microfilarial densities (MFDs) of Loa loa are at risk of developing serious adverse events (SAEs) after ivermectin treatment. Pretreatment with drugs progressively reducing Loa MFDs below the risk threshold might help prevent these SAEs. We assessed the safety and efficacy of levamisole for this purpose. Methods A double-blind, randomized, placebo-controlled, MFD-ascending trial was conducted in the Republic of the Congo. Participants were treated in 3 cohorts defined by pretreatment MFD and levamisole dose (cohort 1: 1.0kg and 1.5mg/kg; cohorts 2 and 3: 2.5mg/kg). Safety outcomes were occurrence of SAE and adverse event frequency during the first week. The efficacy outcomes were MFD reduction from baseline and proportions of individuals with at least 40% and 80% MFD reduction at day 2 (D2), D7, and D30. Results The 2 lowest doses (1.0mg/kg and 1.5mg/kg) caused no SAEs but were ineffective. Compared with placebo, 2.5mg/kg levamisole caused more mild adverse events (10/85 vs. 3/85, P=.018), a higher median reduction from baseline to D2 (-12.9% vs. +15.5%, P<.001), D7 (-4.9% vs. +18.7%, P<.001), and D30 (-0.5% vs. +13.5%, P=.036) and a higher percentage of participants with >40% MFD reduction at D2 (17.5% vs. 1.2%, P<.001), D7 (11.8% vs. 6.3%, P=.269), and D30 (18.5% vs. 9.6%, P=.107). Conclusions A single 2.5mg/kg levamisole dose induces a promising transient reduction in Loa loa MFDs and should encourage testing different regimens.

[1]  M. Boussinesq,et al.  Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study , 2021, British journal of clinical pharmacology.

[2]  J. Vlaminck,et al.  The World Health Organization 2030 goals for onchocerciasis: Insights and perspectives from mathematical modelling , 2019, Gates open research.

[3]  F. Richards,et al.  Progress toward elimination of onchocerciasis in the Americas. , 2018, International health.

[4]  M. Boussinesq,et al.  Alternative treatment strategies to accelerate the elimination of onchocerciasis , 2018, International health.

[5]  J. Keiser,et al.  Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis , 2017, British Medical Journal.

[6]  C. Soman,et al.  Understanding molecular mechanisms in multivariant actions of levamisole as an anti-helminthic, anti-inflammatory, antioxidant, anti-neoplastic and immunomodulatory drug☆ , 2016 .

[7]  L. Coffeng,et al.  Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results , 2016, Infectious Diseases of Poverty.

[8]  J. Kamgno,et al.  Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial , 2016, PLoS neglected tropical diseases.

[9]  Progress toward eliminating onchocerciasis in the WHO Region of the Americas: verification of elimination of transmission in Mexico. , 2015, Releve epidemiologique hebdomadaire.

[10]  L. Konaté,et al.  Proof-of-Principle of Onchocerciasis Elimination with Ivermectin Treatment in Endemic Foci in Africa: Final Results of a Study in Mali and Senegal , 2012, PLoS neglected tropical diseases.

[11]  M. Miller.  Use of Levamisole in Parasitic Infections , 1980, Drugs.

[12]  P. Diggle,et al.  The Geographic Distribution of Loa loa in Africa: Results of Large-Scale Implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA) , 2011, PLoS neglected tropical diseases.

[13]  M. Boussinesq,et al.  A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia. , 2010, The American journal of tropical medicine and hygiene.

[14]  M. Boussinesq,et al.  Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events. , 2009, The American journal of tropical medicine and hygiene.

[15]  L. Konaté,et al.  Feasibility of Onchocerciasis Elimination with Ivermectin Treatment in Endemic Foci in Africa: First Evidence from Studies in Mali and Senegal , 2009, PLoS neglected tropical diseases.

[16]  M. Boussinesq,et al.  Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg). , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[17]  M. Boussinesq,et al.  Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia , 2002, Annals of tropical medicine and parasitology.

[18]  M. Boussinesq,et al.  Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia. , 2002, Parasite.

[19]  M. Boussinesq,et al.  [Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose]. , 2000, Medecine tropicale : revue du Corps de sante colonial.

[20]  M. Boussinesq,et al.  Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection , 1997, The Lancet.

[21]  T. Nutman,et al.  Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. , 1993, The Journal of infectious diseases.

[22]  H. Gilles,et al.  The chemotherapy of onchocerciasis VIII Levamisole and its combination with the benzimidazoles. , 1982, Annals of tropical medicine and parasitology.

[23]  A. R. Rivas-Alcalá,et al.  CHEMOTHERAPY OF ONCHOCERCIASIS: A CONTROLLED COMPARISON OF MEBENDAZOLE, LEVAMISOLE, AND DIETHYLCARBAMAZINE , 1981, The Lancet.

[24]  J. Mak,et al.  Drug trials with levamisole hydrochloride and diethylcarbamazine citrate in Bancroftian and Malayan filariasis. , 1980, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[25]  J. E. Mcmahon.  Preliminary screening of antifilarial activity of levamisole and amodiaquine on Wuchereria bancrofti. , 1979, Annals of tropical medicine and parasitology.

[26]  M. Narasimham,et al.  Levamisole and mebendazole in the treatment of bancroftian infection. , 1978, The Southeast Asian journal of tropical medicine and public health.

[27]  B. Carme,et al.  [Activity of levamisole (Solaskil) in lymphatic filariasis caused by Wucheria bancrofti (variety pacifica]. , 1976, Bulletin de la Societe de pathologie exotique et de ses filiales.

[28]  D. R. O'Holohan,et al.  Treatment of Brugia malayi infection with levamisole. , 1974, The Journal of tropical medicine and hygiene.

[29]  V. Zaman,et al.  Letter: Treatment of Wuchereria bancrofti with levamisole. , 1973, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  F. Hawking,et al.  Periodicity of microfilariae. XII. The effect of variations in host body temperature on the cycle of Loa loa, Monnigofilaria setariosa, Dirofilria immitis and other filariae. , 1967, Transactions of the Royal Society of Tropical Medicine and Hygiene.